Atea Pharmaceuticals, Inc., was incorporated in July 2012 and commenced primary operations in March 2014. The company is a clinical-stage biopharmaceutical company that discovers and develops novel oral product candidates for the treatment of serious viral diseases using a deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry and virology.
